Volume 7, Issue 4 (Summer 2015)                   Iranian Journal of Blood and Cancer 2015, 7(4): 191-194 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Payandeh M, Amirifard N, Sadeghi E, Sadeghi M, Choubsaz M, Noor Mohammadi Far F. The Survey of Effective Agents on Factor VIII and IX Inhibitors in Patients with Hemophilia A and B in Kermanshah Province. Iranian Journal of Blood and Cancer 2015; 7 (4) :191-194
URL: http://ijbc.ir/article-1-615-en.html
1- Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran
2- Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran , sadeghi_mkn@yahoo.com
3- Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
4- Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran
Abstract:   (8642 Views)

 

Background: Hemophilia is the most frequent severe hereditary hemorrhagic disease due to deficiency of coagulation factors VIII (Hemophilia A) or IX (Hemophilia B) in plasma. We aimed to identify patients with  hemophilia in Kermanshah, Iran and assess the incidence of inhibitors in this population and its associated factors.
Methods: This study was conducted on patients with hemophilia A and B admitted in hospitals of Kermanshah city, referred to coagulation laboratory of Kermanshah blood transfusion organization. Variables including age, sex, family history of the patients in terms of history of hemophilia and inhibitor formation, development of inhibitor in patients, age at starting the treatment, blood group, severity of hemophilia, average of factors received per month and liver disease were assessed in patients.
Results: Of 123 patients with hemophilia A, 119 (96.7%) were men. The mean±SD age of patients with hemophilia A was 25.9±15.74 years. Only five men had developed factor VIII inhibitor. Of 25 patients with hemophilia B, 24 (96%) were men with a mean±SD age of 21.7±15.71 years. Factor IX inhibitor was not detected in any patient. There was no association between incidence of inhibitors and age at the onset of the treatment, family history of hemophilia, blood group, severity of hemophilia, average of received factor per month and liver disease. However, a positive association between incidence of inhibitors and family history of inhibitors was found (P<0.05).
Conclusion: Association between family history of inhibitor and incidence of inhibitor formation in hemophilic patients was a new finding. Therefore this outcome and genetic evaluation of these for finding relevant mutations should be considered.
Full-Text [PDF 423 kb]   (2406 Downloads)    
: Original Article | Subject: Adults Hematology & Oncology
Received: 2015/08/12 | Accepted: 2015/10/17 | Published: 2015/10/20

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb